Vol 15, No 4 (2019):185-191

Comparing efficacy of receiving different dosages of eptifibatide in bleeding after percutaneous coronary intervention in patients with myocardial infarction

Hasan Shemirani, Alireza Khosravi, Ali Eghbal, Afshin Amirpour, Farshad Roghani, Seyed Mohammad Hashemi-Jazi, Ali Pourmoghaddas, Ramin Heidari, Amir Sajjadieh, Nahid Sadeghi, Hamid Sanei

DOI: http://dx.doi.org/10.22122/arya.v15i4.1668


BACKGROUND: Acute coronary syndrome (ACS) is a common condition that needs appropriate treatment like percutaneous coronary intervention (PCI). Glycoprotein IIb/IIIa inhibitors (GPI) like eptifibatide prevent procedural ischemic complications after PCI. Eptifibatide has increased the risk of bleeding complications, although it is effective in reducing mortality and morbidity. Eptifibatide is routinely used in bolus and infusion forms and the aim of this study is to evaluate the efficacy of bolus-only dose and bolus + infusion strategy for administrating eptifibatide in bleeding complications and consequences after PCI.

METHODS: This randomized clinical trial was conducted on subjects who experienced PCI after incidence of myocardial infarction (MI). Patients were randomly divided into two groups who received bolus-only dose (n = 51) or bolus + infusion form of eptifibatide (n = 50). Then, PCI blood pressure, mean time duration of hemostasis after arterial sheath removal, laboratory data, need for blood transfusion, and presence of bleeding complications were evaluated. After
6 months, patients were followed for needs for additional coronary interventions.

RESULTS: The mean age of participants was 61.68 ± 1.50 years. The prevalence of men was 70.29%. There was no significant difference in mean of systolic blood pressure (SBP) and diastolic blood pressure (DBP) during hospitalization (P > 0.050). The mean time duration of hemostasis was
8.13 ± 0.45 minutes in the bolus-only group and 16.46 ± 0.71 minutes in the bolus + infusion group (P < 0.001). There was no significant difference in the hemoglobin (Hb) level, platelet count, white blood cell (WBC), blood urea nitrogen (BUN), and creatinine level (P > 0.050).

CONCLUSION: The results of this study suggested that bolus-only dose of eptifibatide before PCI could be able to decrease significantly bleeding complication and other clinical and cardiovascular outcomes.


Eptifibatide; Percutaneous Coronary Intervention; Bleeding; Dosage; Infusion; Myocardial Infarction

Full Text:



Lashari NA, Lakho NI, Memon SA, Ahmed A, Waseem MF. Acute coronary syndrome. The Professional Medical Journal 2017; 24(3): 409-13.

Deibele AJ, Jennings LK, Tcheng JE, Neva C, Earhart AD, Gibson CM. Intracoronary eptifibatide bolus administration during percutaneous coronary revascularization for acute coronary syndromes with evaluation of platelet glycoprotein IIb/IIIa receptor occupancy and platelet function: the Intracoronary Eptifibatide (ICE) Trial. Circulation 2010; 121(6): 784-91.

Boersma E. Primary Angioplasty Vs. fibrinolysis: An overview of randomized trials and registry data. In: De Luca G, Lansky A, Editors. Mechanical reperfusion for STEMI: From randomized trials to clinical practice. Boca Raton, FL: CRC Press; 2016.

Kong DF, Califf RM, Miller DP, Moliterno DJ, White HD, Harrington RA, et al. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation 1998; 98(25): 2829-35.

Srinivasan M, Prasad A. Adjunctive intracoronary antithrombotic therapy: Time to revisit an old strategy? J Invasive Cardiol 2009; 21(5): 224-8.

Gyongyosi M, Domanovits H, Benzer W, Haugk M, Heinisch B, Sodeck G, et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion-results of the Austrian multi-centre randomized ReoPro-BRIDGING Study. Eur Heart J 2004; 25(23): 2125-33.

O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: a randomized controlled trial. JAMA 2001; 285(19): 2468-73.

Rutty GN, Smith P, Visser T, Barber J, Amorosa J, Morgan B. The effect on toxicology, biochemistry and immunology investigations by the use of targeted post-mortem computed tomography angiography. Forensic Sci Int 2013; 225(1-3): 42-7.

O'Shea JC, Buller CE, Cantor WJ, Chandler AB, Cohen EA, Cohen DJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002; 287(5): 618-21.

Fung AY, Saw J, Starovoytov A, Densem C, Jokhi P, Walsh SJ, et al. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol 2009; 53(10): 837-45.

Bertrand OF, De Larochelliere R, Rodes-Cabau J, Proulx G, Gleeton O, Nguyen CM, et al. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation. Circulation 2006; 114(24): 2636-43.

Tenaglia AN, Fortin DF, Califf RM, Frid DJ, Nelson CL, Gardner L, et al. Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. J Am Coll Cardiol 1994; 24(4): 1004-11.

Ellis SG, Bates ER, Schaible T, Weisman HF, Pitt B, Topol EJ. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol 1991; 17(6 Suppl B): 89B-95B.

Topol E, Califf R, Weisman H, Ellis S, Tcheng J, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: Results at six months. Lancet 1994; 343(8902): 881-6.

Gurm HS, Smith DE, Collins JS, Share D, Riba A, Carter AJ, et al. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: Insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol 2008; 51(5): 529-35.

Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JD, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997; 95(4): 846-54.

Tcheng JE. Impact of eptifibatide on early ischemic events in acute ischemic coronary syndromes: a review of the IMPACT II trial. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. Am J Cardiol 1997; 80(4A): 21B-8B.

Kini AS, Chen VH, Krishnan P, Lee P, Kim MC, Mares A, et al. Bolus-only versus bolus+infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Am Heart J 2008; 156(3): 513-9.

Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, et al. Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 2002; 100(6): 2071-6.


  • There are currently no refbacks.

Creative Commons Attribution-NonCommercial 4.0

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.